Reuters logo
BRIEF-Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201
2017年8月28日 / 晚上8点09分 / 3 个月前

BRIEF-Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201

Aug 28 (Reuters) - Daiichi Sankyo Co Ltd

* Bristol-Myers Squibb and Daiichi Sankyo announce research collaboration to evaluate Opdivo (Nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers

* Bristol-Myers Squibb Co - ‍Study is expected to begin enrollment in Q1 of 2018 in US and Europe​

* Bristol-Myers Squibb Co - ‍Under terms of agreement, Daiichi Sankyo will be sponsor conducting trial​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below